Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines
- PMID: 2060546
- DOI: 10.1007/BF00315139
Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines
Abstract
Verapamil, a calcium channel blocker, is used as the racemate. Recently, racemic verapamil has been shown to increase the cytotoxicity of vinca alkaloid and anthracycline derivatives in several resistant tumour cell lines. With respect to its cardiovascular activity S-verapamil is an order of magnitude more potent than R-verapamil. Since it was not known whether the effect on multi-drug resistance was also enantioselective a comparison has been made of the potency of the R and S enantiomers and racemic verapamil in their ability to increase the cytotoxicity of vincristine and daunomycin in sensitive (MOLT 4B) and drug resistant human T-lymphoma cell lines (MOLT/VCR-5 x 9, MOLT/DAU-8 and VCR 1000, a highly resistant subline of CCRF-CEM). Two major metabolites, norverapamil and D617 were tested in the same system. (+)-R, (-)-S-, racemic verapamil, norverapamil and D617 alone had no effect on cell growth in sensitive or resistant cell lines in concentrations up to 20 microM. In combination with vincristine, verapamil and norverapamil but not D617 produced a concentration dependent increase in the sensitivity of the resistant lines. Racemic verapamil, its individual enantiomers and norverapamil were equipotent. The concentration of the modifiers required to elicit 50% of the maximum effect (EC50) was of the order of 0.5 microM. No significant difference in the slopes of the concentration-effect curves were observed. The effect of verapamil and norverapamil was additive. In the sensitive MOLT 4B cell line both enantiomers and norverapamil increased sensitivity towards vincristine. However, the EC50 values were at least an order of magnitude higher (2.5-8 microM) than in the resistant cell lines.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Effect of D,L-verapamil, verapamil enantiomers and verapamil metabolites on the binding of vincristine to alpha 1-acid glycoprotein.Eur J Cancer. 1993;29A(4):559-61. doi: 10.1016/s0959-8049(05)80151-0. Eur J Cancer. 1993. PMID: 8435210
-
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.Drug Metab Dispos. 2004 Feb;32(2):259-66. doi: 10.1124/dmd.32.2.259. Drug Metab Dispos. 2004. PMID: 14744949
-
Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.Anticancer Drugs. 1993 Dec;4(6):605-15. Anticancer Drugs. 1993. PMID: 7905300
-
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.Cancer Chemother Pharmacol. 1992;30(2):152-4. doi: 10.1007/BF00686409. Cancer Chemother Pharmacol. 1992. PMID: 1600596
-
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.Br J Clin Pharmacol. 1999 May;47(5):545-52. doi: 10.1046/j.1365-2125.1999.00923.x. Br J Clin Pharmacol. 1999. PMID: 10336579 Free PMC article.
Cited by
-
Jejunal absorption and metabolism of R/S-verapamil in humans.Pharm Res. 1998 Jun;15(6):856-62. doi: 10.1023/a:1011916329863. Pharm Res. 1998. PMID: 9647350
-
Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.Clin Pharmacokinet. 2002;41(8):533-58. doi: 10.2165/00003088-200241080-00001. Clin Pharmacokinet. 2002. PMID: 12102640 Review.
-
The influence of age and sex on the clearance of cytochrome P450 3A substrates.Clin Pharmacokinet. 2005;44(1):33-60. doi: 10.2165/00003088-200544010-00002. Clin Pharmacokinet. 2005. PMID: 15634031 Review.
-
Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.Cancer Chemother Pharmacol. 1993;31(5):369-75. doi: 10.1007/BF00686150. Cancer Chemother Pharmacol. 1993. PMID: 8431970
-
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.J Cancer Res Clin Oncol. 1995;121 Suppl 3(Suppl 3):R11-6. doi: 10.1007/BF02351065. J Cancer Res Clin Oncol. 1995. PMID: 8698736 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources